HTAi 2021 Virtual Annual Meeting: Intro to Day Three and Day Two Recap


We’re on to Day Three of the HTAi 2021 Annual Meeting, and we hope you’ve enjoyed all of the fantastic presentations so far!

Intro to Day Three

Day Three features a keynote address from Dr Melanie Lee, CEO of LifeArc; five panel sessions; Symposia sessions from Vifor Pharma and Merck & Co. Ltd; Plenary Three: Innovating HTA to Support Novel Interventions; and award presentations followed by the Closing Ceremony. 

Symposia Sessions: SY04, SS04

SY04: Presented by Vifor Pharma 10:15-11:30 (UTC): From NYHA to KCCQ: A Novel Approach to Cost-effectiveness Analysis in Heart Failure (the AFFIRM-AHF Case Study). The Symposium will discuss the advantages and disadvantages of NYHA vs KCCQ, when applied to cost-effectiveness analyses of the recent AFFIRM-AHF trial, which included patients with iron deficiency after an acute HF episode. Specifically, to make economic evidence available when allocating resources, measurement and estimation of outcomes are pivotal for correctly assess a new intervention. Transparently reporting a broader extent of outcomes on top of the functional one (NYHA class) can be of interest of the assessors to better value the money they are going invest in a new health technology. Consequently, this can be inspiring as new method for estimating outcomes, also for other clinical conditions and areas.

SS04: Presented by Merck & Co. Ltd 19:30 – 20:30 (UTC): How Regulatory Bodies and HTA Agencies can Collaborate to Foster Timely Patient Access to Transformative Innovation. In this symposium, the audience will gain greater understanding of the current opportunities and limitations in the regulatory and HTA interface, and how we can optimize this to address future HTA challenges whilst enabling timely patient access.

Read more about our symposia sessions here.

Keynote Three – Dr Melanie Lee, CEO of LifeArc

LifeArc’s CEO Dr Melanie Lee, PhD, CBE. Prior to joining LifeArc Melanie pursued a 30 year career in healthcare R&D and gained leadership experience both from the biopharmaceutical industry and from the medical research charity sector. Melanie’s previous roles have included Chief Scientific Officer at BTG (most recently) as well as senior positions at GSK, Celltech and UCB. She has previously held Trustee appointments at Cancer Research Technology and Cancer Research UK and currently serves on the Board of Directors of Sanofi.

Learn more about Dr Melanie Lee here.

Plenary Three: Innovating HTA to Support Novel Interventions

Discussion is needed to outline the role of HTA bodies regarding the living or continual assessment of novel interventions, particularly for those receiving regulatory approval when evidence is limited.  How can, and should we influence managed entry and commercial agreements, potential disinvestment, and system efficiency with consistency to ensure sustained scientific rigor in decision-making processes, while enhancing rapid uptake of innovation.  At our fingertips is the opportunity to fine tune HTA to the current needs of our decision makers and to adapt to technology advancements. We have the potential to work to support healthcare decision making as a whole by engaging more in early dialogues and building on the opportunities of post-marketing data generation to support cyclical approaches to adopting cost effective and affordable innovation. Bringing key parties together including innovators, payers, HTA doers and clinicians could help us develop new and better assessment methods to evaluate novel interventions.

This plenary will:

  • provide insight into how innovators are working to develop cutting-edge technologies 
  • present examples of innovative interventions, such as Gene Therapies, CAR-T Cell therapy, or Contact Tracing apps, and outline the challenges of meeting the needs of payers at the point of HTA decision making and
  • address how HTA bodies have adapted methodologies and processes to meet decision-maker needs whilst maintaining the rigorous assessment standards and complying with rapid time frames.

Read more about Plenary Three here and the speakers here.

Day Two Recap

Day Two was packed with patient-centered presentations! Delegates were treated to an excellent keynote session from patient advocate Neil Bertelsen, followed by Plenary Two: Patients at the Heart of HTA.

The HTAi social media team is currently running a poll from Plenary Two on LinkedIn. If you haven’t participated yet, submit your vote now!

Catch-up and Connect

Movement and breathing sessions

To alleviate some of the impacts of being sedentary, the Scottish Ballet got our delegates out of their chairs for a series of movement and breathing sessions – a physical and mental boost!

Virtual mixology class

The experts from TT Liquor hosted a captivating virtual mixology class where they led us through two tasty cocktail creations, modelling some core techniques. Annual Meeting delegates had ample opportunity to network and form new connections with fellow attendees.

Want to recreate the cocktails? We’ve got you covered! All cocktail and mocktail recipes are available on our website.

Music from host nations and art class

Attendees had additional options to attend Zentangle, a bite-size art session with Irene Walker from NICE or a rebroadcast of our remarkable performances from UK artists The Ayoub Sisters, the Northern Chamber Orchestra, and Welsh Men’s Choir Only Men Aloud.

The social event sessions were followed by 45 minutes of speed networking to get the conversation going and connections building!

The HTAi Annual Meeting team is sharing and commenting on posts throughout the day. Search the official event hashtag, #HTAi2021VirtualAm, or visit HTAi on Twitter, @HTAiorg, to read what everyone was talking about!

Thank you to our sponsors!

A huge shout out to our sponsors, without whom it would be impossible to stage a meeting of this magnitude and impact: Bayer, Edwards Lifesciences, Takeda, janssen, MSD, Pfizer, Novartis, All Wales Therapeutics & Toxicology Centre (AWTTC), Health Improvement Scotland, Health Technology Wales, National Institute for Health and Care Excellence (NICE), Royal Australasian College of Surgeons, Sanofi, Health Economics and Health Technology Assessment, INTUITIVE, abpi, Cambridge University Press, and the LSE Department of Health Policy.